Inclusion Criteria:
  -  Participant with moderate to severe Hidradenitis Suppurativa (HS) for at least one year prior to Baseline visit.
  -  HS lesions present in at least two distinct anatomical areas.
  -  Draining fistula count of <=20 at Baseline visit.
  -  Total abscesses and nodule count (AN count) of >= 5 at Baseline visit.
  -  Participants are required to use a daily antiseptic wash on their HS lesions .
  -  Participant must have a history of inadequate response or intolerance to an adequate trial of oral antibiotics for treatment of HS.
Exclusion Criteria:
  -  Participant has a history of active skin disease other than HS that could interfere with the assessment of HS.
  -  Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immuno deficiency virus (HIV) infection.
  -  Participant has prior exposure to anti-interleukin-1 (anti-IL-1) treatment within 3 months or 5 half-lives, whichever is longer, prior to baseline.
  -  Participant has received prescription topical therapies (including topical antibiotics) within 14 days prior to the Baseline visit.
  -  Participant has received systemic non-biologic therapies that can also be used to treat HS within 4 weeks prior to the Baseline visit.
  -  Participant has received any systemic (including oral) antibiotic treatment within 4 weeks prior to the Baseline visit.